Motif Bio’s hope of adding to the antibiotic armamentarium for serious bacterial infections has just been dealt a blow by the FDA.
Amgen and Abilita Bio have inked a research deal, focusing on developing drugs for challenging membrane protein targets.
The PD-L1 combination trials led the clear out, and the immuno-oncology drugs tested in those studies feature heavily in the earlier-phase cull.
The deal sees Novartis join GlaxoSmithKline, Merck and Pfizer on the list of companies partnered with the antibody discovery shop.
A team led by the Wyss Institute has created reversible platelets that they say may not only reduce blood clots but might also prevent cancer from spreading.
Johnson & Johnson is diving deeper into robotic surgery with a $3.4 billion deal for Auris Health, designer of endoscopes aimed at lung cancer.
Hologic launched management software for its mammography machines that can predict the failure of X-ray hardware and help schedule early replacements.
Charles River has added another string to its early-stage R&D bow by acquiring preclinical services firm Citoxlab for $510 million in cash.
The deal sees Sygnature take a stake in Pathios in part payment for its involvement in the Oxford-based biotech’s hit-to-lead program.
The panel’s decision to back the ketamine-like drug tees J&J up to win approval for one of the most notable antidepressants in decades.